"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial of AZD8931 with chemotherapy for cancer of the oesophagus or the junction of the stomach and oesophagus (DEBIOC)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Oesophageal cancer is cancer of the food pipe and where the oesophagus meets the stomach is gastro-oesophageal junction cancer.
Both these cancers are treated with the same chemotherapy.
Cancer Research UK supported this trial.
More about this trial
- find the best dose of AZD8931 to have with XELOX chemotherapy
- see if AZD8931 and chemotherapy works better than chemotherapy alone for cancer of the oesophagus or gastro-oesophageal junction
Summary of results
- being sick
- skin rash
- feeling and being sick
- 20 people had AZD8931 and XELOX
- 10 people had XELOX only
- 85 out of every 100 people (85%) for those who had AZD8931 and XELOX
- 100 out of every 100 people (100%) for those who had XELOX only
- 45 out of every 100 people (45%) who had AZD8931 and XELOX
- 90 out of every 100 people (90%)who had XELOX only
- 7 people (35%) in the AZD8931 and XELOX group
- 1 person (10%) in the XELOX only group
- 10 out of every 100 people (10%) in the AZD8931 and XELOX group
- 50 out of every 100 people (50%) in the XELOX only group
How to join a clinical trial
Dr Anne Thomas
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University of Oxford
This is Cancer Research UK trial number CRUKD/12/007.